Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm
DXCM(NASDAQ:DXCM) NEW YORK, Sept. 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, DexCom insiders...
Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day
DXCM(NASDAQ:DXCM) SAN DIEGO & BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond. Now through Sept. 19, people from 2 years and older living with all types of diabetes and
Dexcom Announces Upcoming Conference Presentations
DXCMSAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT) The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT) Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for futur
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025
DXCMSAN DIEGO--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, today released its Dexcom State of Type 2 Report: Access and Attitudes Across the United States ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States. During the conference, Dexcom will p
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
DXCMSAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purpo
Forecasting The Future: 7 Analyst Projections For DexCom
DXCMGoldman Sachs Initiates Coverage On DexCom with Buy Rating
DXCMGoldman Sachs Initiates Coverage On DexCom with Buy Rating
DXCMCitigroup Maintains Buy on DexCom, Raises Price Target to $102
DXCMThe End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
DXCMis it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Dexcom Promotes Jake Leach To President And COO
DXCMWhat's Driving the Market Sentiment Around DexCom?
DXCMBarclays Maintains Equal-Weight on DexCom, Raises Price Target to $93
DXCMCanaccord Genuity Maintains Buy on DexCom, Raises Price Target to $106
DXCMPiper Sandler Maintains Overweight on DexCom, Lowers Price Target to $90
DXCMBaird Maintains Outperform on DexCom, Lowers Price Target to $105
DXCMDexCom Affirms FY2025 Sales Guidance of $4.60B vs $4.61B Est
DXCMDexCom Q1 Adj. EPS $0.32 Misses $0.33 Estimate, Sales $1.04B Beat $1.02B Estimate
DXCMA Look Into DexCom Inc's Price Over Earnings
DXCMWhat Does the Market Think About DexCom?
DXCMFDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
DXCMDexcom G7 15-Day CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features.
Dexcom Receives FDA Clearance For G7 15 Day Continuous Glucose Monitoring System
DXCMWhat 6 Analyst Ratings Have To Say About DexCom
DXCMMizuho Initiates Coverage On DexCom with Outperform Rating, Announces Price Target of $85
DXCMIs DexCom Gaining or Losing Market Support?
DXCMDexCom Announced The Launch Of Its First Multi-region Report, The Dexcom State Of Type 2 Report: Access And Attitudes Across Europe And The Middle East.
DXCMCitigroup Maintains Buy on DexCom, Raises Price Target to $104
DXCMDexCom Analysts Increase Their Forecasts After Q4 Earnings
DXCMCanaccord Genuity Maintains Buy on DexCom, Raises Price Target to $103
DXCMMorgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $82
DXCMDexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More
DXCMDexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.
Dexcom Sees FY25 Adj. EBITDA Margin 30%; Revenue Growth 14%; FY25 Revenue $4.60B.
DXCMDexCom Q4 2024 Adj. EPS $0.45 Misses $0.50 Estimate, Sales $1.140B Beat $1.104B Estimate
DXCMDexCom Currently Anticipates FY25 Total Revenue Of $4.60B, Representing Expected Growth Of 14% Over 2024; Est $4.608B
DXCMDexCom Expects Q4 Total Revenue Of At Least $1.113B, Up 8% YoY (Est $1.097B); Expects Gross Margin To Be Adversely Impacted By Non-cash Charge
DXCMDexCom, ŌURA Enter Strategic Partnership; Dexcom Is Investing $75M In Ōura Series D Funding
DXCMIf You Invested $1000 In DexCom 10 Years Ago, Here's How Much You Would Have Today
DXCMDexCom (NASDAQ:DXCM) has outperformed the market over the past 10 years by 32.66% on an annualized basis producing an average annual return of 44.4%. Currently, DexCom has a market capitalization of $39.95 billion.
Read Here Why Did This Analyst Cut DexCom's Price Target
DXCMRaymond James Maintains Outperform on DexCom, Lowers Price Target to $486
DXCMMorgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $492
DXCMPiper Sandler Maintains Overweight on DexCom, Lowers Price Target to $480
DXCMSVB Leerink Maintains Outperform on DexCom, Lowers Price Target to $500
DXCMRecap: DexCom Q1 Earnings
DXCMDexCom (NASDAQ:DXCM) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
DexCom missed estimated earnings by 38.46%, reporting an EPS of $0.32 versus an estimate of $0.52.
DexCom Q1 EPS $0.32 Misses $0.52 Estimate, Sales $628.80M Beat $623.36M Estimate
DXCM